ReviewPakistan journal of medical sciences2014
Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review.
Review in Pakistan journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Disabled-2, a versatile tissue matrix multifunctional scaffold protein with multifaceted signaling: Unveiling its potential in the cancer battle.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.IET systems biology · 2023Article
- Identification and Validation of a Prognostic Signature Based on Methylation Profiles and Methylation-Driven GeneDisease markers · 2022Article
- Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder.Diagnostics (Basel, Switzerland) · 2020Article
- Epstein-Barr virus miR-BART1-3p suppresses apoptosis and promotes migration of gastric carcinoma cells by targeting DAB2.International journal of biological sciences · 2020Article
- Emerging Roles of Disabled Homolog 2 (DAB2) in Immune Regulation.Frontiers in immunology · 2020Review
- A new BCR-ABL1Haematologica · 2019Article
- 17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression.Scientific reports · 2017Article
- Inherited pancreatic cancer.Chinese clinical oncology · 2017Review
- Article
- Integrated analysis of gene expression and DNA methylation changes induced by hepatocyte growth factor in human hepatocytes.Molecular medicine reports · 2015Article
- Disabled homolog 2 is required for migration and invasion of prostate cancer cells.Frontiers of medicine · 2015Article
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Oncotarget · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective : Disabled-2 (Dab2) is an important endocytic adaptor which plays an inhibition role in cancer cell growth. The objective of this study was to systematically review expressions of Dab2 in human cancers. Methods : Eligible studies about Dab2 in human cancers were retrieved from databases of PubMed, Embase, Web of Science. Odds Ratios (ORs) with 95% confidence intervals (CIs) were calculated using Review Manager 5.0 software and statistical analyses were performed by the SPSS 13.0 software. Results : Fourteen case-control studies with a total of 689 human tumor tissues, 332 control tissues and 32 cancer cell lines were included in the meta-analysis study. The results indicated loss expressions of Dab2 were observed in 74.9% and 46.9% in human malignant cancer tissues and cancer cell lines, respectively. The ratio of Dab2 promotor hypermethylation is 34.54% in cancer tissues which Dab2 expression are lost, but none in the control tissues or cells by Methylation-specific PCR (MSP). Conclusions : The expressions of Dab2 are frequently lost in human malignant cancer tissues, and promotor hypermethylation of Dab2 are common in human malignant cancer tissues, which is an important factor for the loss expression of Dab2 in human cancers tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.